October - 2022

Oct 31, 2022

Helicobacter bilis Contributes to the Occurrence of Inflammatory Bowel Disease

Helicobacter bilis Contributes to the Occurrence of Inflammatory Bowel Disease by Inducing Host Immune Disorders. Wei Peng, Xinhua Zhao, Xiaoan Li Published in Aug 2022, BioMed research international. Abstract Gut microbiota coevolve with humans to achieve a symbiotic relationship, which ultimately leads to physiological homeostasis. A variety of diseases can occur once this balance is disrupted. Helicobacter bilis (H. bilis) is an opportunistic pathogen in humans, triggering

IBDENC ENC

Oct 29, 2022

Assessing Cellular and Transcriptional Diversity of Ileal Mucosa Among Treatment-Naïve

Assessing Cellular and Transcriptional Diversity of Ileal Mucosa Among Treatment-Naïve and Treated Crohn’s Disease. Sushma Chowdary Maddipatla, Vasantha L Kolachala, Suresh Venkateswaran, Anne F Dodd, Ranjit Singh Pelia, Duke Geem, PhD,Hong Yin, Yutong Sun, Congmin Xu, Angela Mo, Astrid Kosters, Junkai Yang, Jason D Matthews, Eliver Ghosn, Subra Kugathasan, Peng Qiu Published: 07 October 2022 Abstract Background Crohn’s disease is a lifelong disease characterized by chronic i

IBDENC ENC

Oct 28, 2022

An autologous colonic organoid-derived monolayer model to study immune

An autologous colonic organoid-derived monolayer model to study immune: bacterial interactions in Crohn's disease patients. Hamish CK Angus, Paulo CM Urbano, Gemma A Laws, Shijun Fan, Safina Gadeock, Michael Schultz, Grant Butt, Andrew J Highton, Roslyn A Kemp Published in Aug 2022, Clinical & translational immunology. Abstract Objectives Crohn's disease (CD) initiation and pathogenesis are believed to involve an environmental trigger in a genetically susceptible person that

IBDENC ENC

Oct 25, 2022

Effect of risankizumab on health-related quality of life in patients with Crohn's disease

Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Laurent Peyrin-Biroulet, Subrata Ghosh, Scott D. Lee, Wan-Ju Lee, Jenny Griffith, Kori Wallace, Sofie Berg, Xiaomei Liao, Julian Panes, Edward V. Loftus Jr, Edouard Louis Published: 20 October 2022 Summary Background Crohn's disease has a substantial negative impact on health-related quality of life (HRQoL).Aim To exami

IBDENC ENC

Oct 23, 2022

Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease

Benjamin Langan Gordon, Jonathan S Galati, Stevie Yang, Randy S Longman, Dana Lukin, Ellen J Scherl, Robert Battat Published in Sep 2022, World journal of gastroenterology. BACKGROUND Patients with inflammatory bowel disease (IBD) are prone to several nutritional deficiencies. However, data are lacking on vitamin C deficiency in Crohn’s disease (CD) and ulcerative colitis (UC) patients, as well as the impact of clinical, biomarker and endoscopic disease severity on the develo

IBDENC ENC

Oct 22, 2022

Prediction of Crohn’s Disease Stricturing Phenotype Using a NOD2-derived Genomic Biomarker

James J Ashton, Guo Cheng, Imogen S Stafford, Melina Kellermann, Eleanor G Seaby, J R Fraser Cummings, Tracy A F Coelho, Akshay Batra, Nadeem A Afzal, R Mark Beattie, Sarah Ennis Published in Sep 2022, Inflammatory bowel diseases. Abstract Background Crohn’s disease (CD) is highly heterogenous and may be complicated by stricturing behavior. Personalized prediction of stricturing will inform management. We aimed to create a stricturing risk stratification model using genomic/c

IBDENC ENC

Oct 21, 2022

New endoscopic tools in inflammatory bowel disease

Olga Maria Nardone, Rosanna Cannatelli, Subrata Ghosh, Marietta Iacucci Published: 12 October 2022 Abstract Endoscopic remission is now considered the ultimate long-term goal for treating inflammatory bowel disease (IBD). Recent advances in endoscopic techniques have progressively added new tools to the armamentarium of endoscopists for a deeper assessment and characterization of the intestinal mucosa. Virtual Electronic chromoendoscopy is widely available in the endoscopic u

IBDENC ENC

Oct 19, 2022

Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease

Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study. Aamir Saifuddin, Alexandra J. Kent, Shameer J. Mehta, Lucy C. Hicks, Haidee A. Gonzalez, Jonathan P. Segal, Matthew J. Brookes, Sreedhar Subramanian, Neeraj Bhala, Thomas E. Conley, Kamal V. Patel, PREPARE-IBD Collaborators, Christopher A. Lamb, Gareth J. Walker, Nicholas A. Kennedy, Shaji Sebastian Publish

IBDENC ENC

Oct 19, 2022

Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients

Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region. Peeyush Kumar, Sudheer K Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet

IBDENC ENC

Oct 19, 2022

Real world population pharmacokinetic study in children and young adults with inflammatory bowel

Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance. Ruben J. Colman, Tomoyuki Mizuno, Keizo Fukushima, David B. Haslam, Jeffrey S. Hyams, Brendan Boyle, Joshua D. Noe, Geert R. D'Haens, Johan Van Limbergen, Kelly Chun, Jane Yang, Lee A. Denson, Nicholas J. Ollberding, Alexander A. Vinks, Phillip Minar Published: 31 October 2022 Summary Background

IBDENC ENC

Oct 19, 2022

Validating the Simplified Endoscopic Mucosal Assessment for Crohn’s Disease

Validating the Simplified Endoscopic Mucosal Assessment for Crohn’s Disease: A Novel Method for Assessing Disease Activity. Jeremy Adler, Richard B Colletti, Lenore Noonan, Tyler M Berzin, Adam S Cheifetz, Laurie S Conklin, Timothy C Hoops, Christopher S Huang, Blair Lewis, Daniel S Mishkin, Kim Hung Lo, Yongling Xiao, Sheri Volger Published in Sep 2022, Inflammatory bowel diseases. Abstract Background To demonstrate treatment efficacy in Crohn’s disease (CD), regulatory auth

IBDENC ENC

Oct 18, 2022

Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients

Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open Luc Biedermann, MD, Marla C Dubinsky, MD, Séverine Vermeire, MD, Marc Fellmann, PhD, Sean Gardiner, MD, Peter Hur, PharmD, Rajiv Mundayat, MSc, Julian Panés, MD, David T Rubin, MD Published: 15 October 2022 Abstract Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. W

The Mission

Key Opinion Leaders

International

Advisory Board

Initiatives

Discuss a case

Journal Scan

Latest News

Education Hub

Gallery